Can we develop mutation-specific therapies?

Targeted APOE4-to-APOE3 Base Editing Therapy

candidate answer · hypothesis · 82%

CRISPR Gene Correction Approaches for CBS/PSP

partial answer for · experiment · 70%

Clinical outcome analysis based on IDH mutation status

partial answer for · experiment · 65%

LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD

discriminating experiment · experiment · 62%

TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeutic Exploitation

partial answer for · experiment · 60%

Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown

partial answer for · experiment · 58%

FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutation Carriers Develop FXTAS

partial answer for · experiment · 58%

AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy

partial answer for · experiment · 55%

AAV-LRRK2 Gene Therapy IND-Enabling Study Design

partial answer for · experiment · 52%

AAV-LRRK2 IND-Enabling Study Design

partial answer for · experiment · 52%

Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring

bears on question · hypothesis · 40%

Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring

hypothesis | bears_on_question

Targeted APOE4-to-APOE3 Base Editing Therapy

hypothesis | candidate_answer